BioMarin Pharma(BMRN.US)

Last Updated 19:00:00 ET
longbridge loading

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Simplywall·
US
BMRN
+0.84%
US
XBI
-0.11%
US
SBIO
-0.32%
Simplywall·
US
BMRN
+0.84%
US
XBI
-0.11%
US
SBIO
-0.32%

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

TradingView·
US
BMRN
+0.84%
US
IHE
+1.01%
US
BIB
+0.67%
TradingView·
US
BMRN
+0.84%
US
IHE
+1.01%
US
BIB
+0.67%

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News

StockTitan·
US
BMRN
+0.84%
StockTitan·
US
BMRN
+0.84%

Cantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple Sclerosis

Unusual Whales·
US
BMRN
+0.84%
US
IBBQ
+0.65%
US
IXJ
+0.90%
Unusual Whales·
US
BMRN
+0.84%
US
IBBQ
+0.65%
US
IXJ
+0.90%

Here are Monday’s top Wall Street analyst research calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and more

MSN·
US
BMRN
+0.84%
US
TTD
-2.96%
US
DELL
+0.45%
MSN·
US
BMRN
+0.84%
US
TTD
-2.96%
US
DELL
+0.45%
© 2026 Longbridge｜Disclaimer